These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3548648)

  • 1. Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies.
    Teelmann K; Hohbach C; Lehmann H
    Arch Toxicol; 1986 Dec; 59(4):195-200. PubMed ID: 3548648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preclinical evaluation of the safety of biotechnology products: specific aspects].
    Descotes J; Ravel G; Vial T
    Therapie; 2003; 58(2):139-43. PubMed ID: 12942854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of biopharmaceuticals in laboratory animals.
    Wierda D; Smith HW; Zwickl CM
    Toxicology; 2001 Feb; 158(1-2):71-4. PubMed ID: 11164995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
    Martin PL; Weinbauer GF
    Int J Toxicol; 2010 Dec; 29(6):552-68. PubMed ID: 20926830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.
    Bugelski PJ; Treacy G
    Curr Opin Mol Ther; 2004 Feb; 6(1):10-6. PubMed ID: 15011776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do preclinical testing strategies help predict human hepatotoxic potentials?
    Peters TS
    Toxicol Pathol; 2005; 33(1):146-54. PubMed ID: 15805066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY; Johnson RC; Schmahai TJ
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of biotechnology products.
    Zbinden G
    Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The developmental toxicity testing of biologics.
    Hazelden KP
    Methods Mol Biol; 2013; 947():31-6. PubMed ID: 23138893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotechnology products intended for human use, toxicological targets and research strategies.
    Zbinden G
    Prog Clin Biol Res; 1987; 235():143-59. PubMed ID: 2440056
    [No Abstract]   [Full Text] [Related]  

  • 19. The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra.
    van Mierlo GJ; Cnubben NH; Kuper CF; Wolthoorn J; van Meeteren-Kreikamp AP; Nagtegaal MM; Doornbos R; Ganderup NC; Penninks AH
    J Immunotoxicol; 2013; 10(1):96-105. PubMed ID: 23134195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.